Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
<p>Abstract</p> <p>Background</p> <p>Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their molecular transducers...
Main Authors: | Bardelli Alberto, Risio Mauro, Chiorino Giovanna, Casorzo Laura, Migliardi Giorgia, Cavalloni Giuliana, Penachioni Junia Y, Peraldo-Neia Caterina, Sarotto Ivana, Pignochino Ymera, Aglietta Massimo, Leone Francesco |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/631 |
Similar Items
-
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
by: Chiara Varamo, et al.
Published: (2019-04-01) -
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
by: Caterina Peraldo-Neia, et al.
Published: (2021-04-01) -
Assessment of a High Sensitivity Method for Identification of <i>IDH1</i> R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients
by: Caterina Peraldo-Neia, et al.
Published: (2019-03-01) -
Evolution of the Experimental Models of Cholangiocarcinoma
by: Annamaria Massa, et al.
Published: (2020-08-01) -
HKI-272 contributes to gemcitabine-mediated anti-proliferative and anti-metastatic effects through EGFR suppression in gallbladder cancer
by: Xuli Yang, et al.
Published: (2022-12-01)